ArticleTranslational neurodegeneration2023

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.

Alireza Faridar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.